• Roche’s Genentech won FDA priority review for Gazyva to treat adults with primary membranous nephropathy.
• FDA decision expected by November 2026; application backed by Phase III MAJESTY data showing 36.9% complete remission at 104 weeks vs 5.7% for tacrolimus.
• Gazyva previously received FDA Breakthrough Therapy designation in this indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714394570) on July 15, 2026, and is solely responsible for the information contained therein.